Update to the Biosimilar Preferred Drug List (PDL)
Effective January 1, 2025, the Department will add preferred and non-preferred drugs to the Biosimilar PDL, listed below.
Preferred drugs:
- Q5108 – Fulphila, pegfilgrastim-jmdb
Non-preferred drugs: